Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have advanced cancer treatment. Sunitinib, a recently-approved, multi-targeted TKI, prolongs survival for patients with metastatic renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST), but concerns about cardiac safety have arisen with th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chu, Tammy F., Rupnick, Maria A., Kerkela, Risto, Dallabrida, Susan M., Zurakowski, David, Nguyen, Lisa, Woulfe, Kathleen, Pravda, Elke, Cassiola, Flavia, Desai, Jayesh, George, Suzanne, Morgan, Jeffrey A., Harris, David, Ismail, Nesreen S., Chen, Jey-Hsin, Schoen, Frederick J.
Format: Artigo
Idioma:Inglês
Publicat: 2007
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2643085/
https://ncbi.nlm.nih.gov/pubmed/18083403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(07)61865-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars